Compounded medications are mixed by licensed pharmacies under Section 503A (patient-specific) or 503B (outsourcing facility) of the FD&C Act. Compounded drugs are not FDA-approved and do not undergo brand-equivalent manufacturing oversight. Most compounded GLP-1s sold by telehealth platforms during the 2023-2025 shortage were produced under 503A or 503B authority. With the shortage officially resolved (May 2026), compounded sales are facing tighter FDA enforcement.
Also known as
compounded semaglutidecompounded tirzepatide
Related terms
- GLP-1
- Glucagon-like peptide-1 receptor agonist — class of drugs that mimic a gut hormone to reduce appetite and slow stomach emptying.
- Semaglutide
- GLP-1 receptor agonist; active ingredient in Wegovy, Ozempic, and Rybelsus.
- Tirzepatide
- Dual GIP/GLP-1 receptor agonist; active ingredient in Mounjaro and Zepbound.